

July 22, 2021

<b>National Stock Exchange of India Ltd</b> <b>Listing Department</b> Exchange Plaza, 5th Floor, Plot No: C/1, G - Block, Bandra — Kurla Complex, Bandra (East), Mumbai - 400 051 NSE Symbol: ORCHPHARMA	<b>BSE Limited</b> <b>Corporate Relationship Department</b> 1st floor, New Trading Ring, Rotunda Building, P J Towers, Dalal Street, Fort Mumbai - 400 001 BSE Code: 524372
<b>Luxembourg Stock Exchange</b> <b>Bourse de Luxembourg</b> BP 165, L-2011 Luxembourg Siege social 11, avenue de la Portal - Neuve	<b>London Stock Exchange</b> 10 Paternoster Square London EC4M 7LS United Kingdom

Dear Sir/ Madam

**Intimation under Regulation 30 read with Schedule III of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject and in furtherance of our communication submitted to your good office on May 06, 2021, we would like to inform you that Orchid Pharma Limited ("the Company") has signed a Business Transfer Agreement on July 21, 2021 for transfer of its NPNC Formulations Division (IKKT Undertaking) at Irungattukottai, Chennai to a Joint Venture with a subsidiary of Bionpharma, a US based generic pharmaceutical company with a commercial portfolio and a pipeline of generic products in the United States.

This strategic collaboration will help Orchid expand its Formulations base in Regulated Markets with a strong partner with a presence in US, which is especially important in light of current pandemic. The consummation of the transaction is subject to satisfactory completion of conditions precedent including the approval of Shareholders of Orchid and Other approvals.

Kindly take the above information on your records.

Thanking you,

Yours faithfully,



Nikita K  
Company Secretary